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In Brief
TGF-b signaling has an unquestionable
but still controversial role in the
pathogenesis of aortic aneurysm. Da Ros
et al. demonstrate that disruption of
TGF-b signaling in SMCs activates an
autocrine IL-1b pathway that acts as a
danger signal to recruit innate immune
cells in the adventitia through CCL2.
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Aortic aneurysms are life-threatening conditions with
effective treatments mainly limited to emergency
surgery or trans-arterial endovascular stent grafts,
thus calling for the identification of specificmolecular
targets. Genetic studies have highlighted controver-
sial roles of transforming growth factor b (TGF-b)
signaling in aneurysm development. Here, we report
on aneurysms developing in adult mice after smooth
muscle cell (SMC)-specific inactivation of Smad4, an
intracellular transducer of TGF-b. The results
revealed that Smad4 inhibition activated inter-
leukin-1b (IL-1b) in SMCs. This danger signal later
recruited innate immunity in the adventitia through
chemokine (C-C motif) ligand 2 (CCL2) and modified
the mechanical properties of the aortic wall, thus fa-
voring vessel dilation. SMC-specific Smad4 deletion
in Il1r1- orCcr2-null mice resulted inmilder aortic pa-
thology. A chronic treatment with anti-IL-1b antibody
effectively hampered aneurysm development. These
findings identify a mechanistic target for controlling
the progression of aneurysms with compromised
TGF-b signaling, such as those driven by SMAD4
mutations.
INTRODUCTION
Defined as a progressive dilation of the vessel, with tube-shaped
(fusiform) or round (saccular) enlargements, aortic aneurysms
are a significant cause of mortality and morbidity in the western
world; they have no clinical treatment other than high-risk sur-
gery or trans-arterial endovascular therapies with stent grafts
when the conditions of patients are favorable to this option (Da-
vis et al., 2014; Milewicz et al., 2008). However, the indication for
intervention is generally reserved for large aneurysms, and no
effective therapy contrasts the evolution of aneurysms at initial
stages. This shortage of clinical approaches is mainly a resultImof insufficient insights into the early pathogenetic mechanisms
of aneurysm formation. Among the proposed signals involved,
components of the transforming growth factor b (TGF-b)
pathway have an unquestionable but still controversial role in
the pathogenesis of aortic aneurysms (Gillis et al., 2013; Lindsay
and Dietz, 2011).
When mutated, genes encoding components of the TGF-b
pathway can cause the formation of aortic aneurysms, leading
to, for instance, Loeys-Dietz syndrome (LDS) (Gillis et al.,
2013). The observation that aortic tissue from LDS patients has
defective TGF-b signaling components but paradoxically
enhanced TGF-b activity, as shown by increased phosphoryla-
tion of its downstream intracellular signaling SMAD2, led to the
proposal that TGF-b hyperactivity accounts for the aortic pathol-
ogy (Gillis et al., 2013; Holm et al., 2011). However, it should not
be neglected that other studies have suggested a protective role
of TGF-b activity in the process of aneurysm development (Ber-
toli-Avella et al., 2015; Lindsay et al., 2012; van de Laar et al.,
2011; Yang et al., 2016).
The TGF-b pathway is mediated through the phosphorylation
of and interaction between Smad2 and Smad3 and the common
interactor Smad4, which all form a complex that regulates gene
transcription in the nucleus (Shi and Massague´, 2003). Human
syndromes resulting from SMAD4 mutations also include high-
frequency aortic aneurysms (Andrabi et al., 2011; Heald et al.,
2015; Teekakirikul et al., 2013). Given that Smad4 is an obliga-
tory component of the canonical TGF-b pathway, targeting its
encoding gene has been exploited as a strategy for unraveling
the role of TGF-b signaling in aortic pathology. Because whole-
genome Smad4 ablation is embryonically lethal in mice, Zhang
et al. recently demonstrated that the conditional deletion of
Smad4 in Acta2-expressing smooth muscle cells (SMCs) in-
duces aortic aneurysms (Zhang et al., 2016). Although it informs
the causal link between Smad4 loss of function and aneurysm
formation, the pathology developed in these mice is very severe
and does not allow thorough investigation of the mechanisms.
To this aim, we induced a targeted deletion of Smad4 in adult
mice by using a tamoxifen-inducible Cre recombinase under the
control of the SMC promoter. This study demonstrates a key
mechanistic role of structural alterations and immune and inflam-
matory processes driven by interleukin-1b (IL-1b) produced bymunity 47, 959–973, November 21, 2017 ª 2017 Elsevier Inc. 959
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SMCs in aortic aneurysms deriving from disrupted canonical
TGF-b signaling in SMCs. The activation of IL-1b as a danger
signal of SMCs subsequently recruits innate immune cells by
activating monocyte chemoattractant protein 1 (MCP-1), also
referred to as chemokine (C-C motif) ligand 2 (CCL2), and its
cognate receptor C-C chemokine receptor type 2 (CCR2).
More important, administration of a neutralizing anti-IL-1b anti-
body protects against the evolution of aortic pathology, opening
the way to translational therapeutic approaches in aneurysms
with compromised canonical TGF-b signaling, such as those
driven by SMAD4 mutations.
RESULTS
Deletion of SMC-Specific Smad4 in Adult Mice Causes
Aneurysmal Formation in the Aorta
To dissect the causal link between defective TGF-b signaling in
the vasculature and aneurysm formation, we generated a murine
model with SMC-specific deletion of Smad4, the common intra-
cellular interactor of canonical TGF-b signaling. To avoid the
confounding effects of inactivation of TGF-b signaling during
development, we used an inducible Cre-loxP system driven by
a smooth muscle myosin heavy chain promoter, Myh11, to
delete Smad4 selectively in SMCs of adult mice. We treated
Smad4f/f;Myh11-creERT2 mice (abbreviated as Smad4-SMC in
the figures) with tamoxifen to allow Cre-mediated recombination
of Smad4 in SMCs (referred to as Smad4-SMCiko mice in the
figures), whereas control groups received only vehicle (referred
to as Smad4-SMCWT mice in the figures). Analysis of Smad4 in
aortas dissected 1 week later showed lower amounts in tamox-
ifen-treated mice than in animals that had received vehicle alone
(Figure S1A). Additional analyses showed that less Smad4 was
specifically detectable in tamoxifen-treated mice carrying
the Smad4 mutation than in mice without the mutation
(Smad4+/+;Myh11-creERT2) (Figure S1A). Immunofluorescence
analysis further demonstrated that the deficiency of Smad4
was confined to the media layer and did not affect the endothe-
lium (Figures S1B and S1C).
Before proceeding with the characterization of aortic pathol-
ogy, we assessed the general cardiovascular function of tamox-
ifen-treated Smad4f/f;Myh11-creERT2 mice and vehicle-treated
Smad4f/f;Myh11-creERT2 mice at day 0 and the following time
points. Initial (basal) and final (16 weeks) analyses, shown in
Table S1, indicated that SMC-specific Smad4 deletion affected
neither blood pressure nor cardiac structure and function. SerialFigure 1. Deletion of SMC-Specific Smad4 in Adult Mice Determines A
(A and B) Representative sequential ultrasound imaging of the ascending aortas
dilation and aneurysm formation (n = 9 mice per group). Scale bars, 1 mm.
(C) Ascending aortic diameters of n = 9 mice per group were quantitatively anal
F(interaction) = 67.80.
(D) Anterior view of the thoracic cavity shows heart and great vessels of mice 16
clearly visible on the lateral side of the ascending aorta in Smad4-SMCiko mice.
(E) Schematic representation of the entire aorta shows the different segments ana
Smad4-SMCiko mice.
(F and G) Progression of abdominal aorta pathology in Smad4-SMCiko mice (G)
(H) Quantitative analysis of abdominal aortic diameters of n = 9 mice per group.
(I) Kaplan-Meier plot for Smad4-SMCiko (n = 17) and Smad4-SMCWT (n = 15) mic
df = 1, c2 = 34.62, p < 0.0001. *p < 0.05, **p < 0.01, ***p < 0.001.
Please also see Figures S1A–S1C, S7A, and S7B.ultrasonographical analyses of the whole aorta, performed every
4 weeks for up to 16 weeks starting at day 0 after tamoxifen or
vehicle administration, revealed that the aortas of Smad4f/f;
Myh11-creERT2 mice treated with tamoxifen progressively
enlarged, whereas none of the vehicle-treated control mice
showed any significant variation from their basal condition (Fig-
ures 1A–1C).
At gross autoptic examination, all aortas of Smad4f/f;Myh11-
creERT2 mice treated with tamoxifen displayed one or more
evident pathologies, mainly manifested as enlargements and
dilations, whereas aortas from Smad4f/f;Myh11-creERT2 mice
treated with vehicle appeared normal (Figure 1D). Regarding
the prevalence of aortic pathologies, we found 100%penetrance
in Smad4f/f;Myh11-creERT2 mice treated with tamoxifen, and
the timing of their appearance varied by aortic region (Figure 1E
schematically depicts the locations of the aneurysms). The
ascending portion of the aorta showed a mildly enlarged
diameter at 4 weeks and culminated in the formation of
aneurysms at 8 weeks (Figures 1A–1C). Conversely, ultrasono-
graphic monitoring of the abdominal aorta revealed that aneu-
rysms formed later at 12 weeks (Figures 1F–1H). Because of
the earliest aneurysmal appearance in the ascending aorta, we
focused our mechanistic evaluations on this location throughout
the study.
As shown in the Kaplan-Meier plot, the survival of Smad4f/f;
Myh11-creERT2 mice treated with tamoxifen was severely
reduced after Smad4 deletion, whereas none of the control
Smad4f/f;Myh11-creERT2 mice treated with vehicle died during
the observation time (Figure 1I). In particular, the mortality of
Smad4f/f;Myh11-creERT2 mice treated with tamoxifen was
nearly 30% during the time frame of ultrasonographic analysis
(i.e., within 16 weeks after Smad4 deletion), when mice died of
aneurysm rupture, as indicated by the presence of hemothorax
at necropsy.
Structural disarrangement of the ascending aorta media in
Smad4f/f;Myh11-creERT2 mice treated with tamoxifen was
clearly appreciated asdiscrete breaks of elastic lamellae 8weeks
after tamoxifen-induced Smad4 deletion (Figures 2A–2C). Unlike
aortopathies, which are characterized by degenerative changes
and identified as cystic medial necrosis (Guo et al., 2001), the
islands of damage detected in the aortas of Smad4f/f;Myh11-
creERT2 mice treated with tamoxifen were not deprived of cells
but rather contained groups of cells with spindle-shaped nuclei
(Figure S1D). In addition, the sites of break did not show amor-
phous matrix deposition, as implied by the reduction ofneurysm Formation in Ascending and Abdominal Aortas
of Smad4-SMCWT (A) and Smad4-SMCiko (B) mice shows progressive vessel
yzed by ultrasound imaging. Two-way ANOVA for repeated measures: df = 4,
weeks after treatment with vehicle (top) or tamoxifen (bottom). Aneurysms are
lyzed and indicates the locations where aneurysms developed (black arrows) in
and control mice (F). Scale bars, 1 mm.
Two-way ANOVA for repeated measures: df = 4; F(interaction) = 16.34.
e shows significantly increased mortality after Smad4 deletion. Log rank test:
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Figure 2. Deletion of SMC-Specific Smad4 in Adult Mice Determines Disarrangement of Aortic Wall
(A and B) Staining of consecutive sections of ascending aorta with Weigert reagent (A) or hematoxylin and eosin H&E (B). Elastic lamellae breaks are indicated by
arrows in sections stained with Weigert reagent; the corresponding sites in H&E-stained sections are marked by arrowheads. Scale bars, 50 mm.
(C) Quantitation of breaks of elastic lamellae in ascending aorta. n = 11 mice per group at 8 weeks and 4 mice per group at 16 weeks. Two-way ANOVA: df = 1;
F(interaction) = 10.30; **p < 0.01, ***p < 0.001.
(D) Remodeling of the wall structure of ascending aorta. Representative sections of ascending aortas from 11 mice per group at 8 weeks and 4 mice per group at
16 weeks were stained with antibodies to a-SMA and ER-TR7, an antigen expressed by adventitial fibroblasts. Scale bars, 50 mm.
Please also see Figures S1D–S1H.histochemical staining formucopolysaccarides (Figures S1E and
S1F). Immunostaining for collagen I in lamellae breaks was lower
in the media of Smad4f/f;Myh11-creERT2 mice treated with962 Immunity 47, 959–973, November 21, 2017tamoxifen than in that of control Smad4f/f;Myh11-creERT2
mice treated with vehicle (Figures S1G and S1H). With time,
the severity of damage increased (Figures 2A–2C, 16 weeks),
and zones with staked fragmentations of elastic lamellae
became apparent (Figure 2A, 16 weeks, arrow).
In the adventitia of the aortas of Smad4f/f;Myh11-creERT2
mice treated with tamoxifen, structural remodeling also deter-
mined a thickening of this layer (asterisks in Figure 2A) and, at
some sites, penetration of cells into the media. This process
could be followed by staining of adventitial fibroblasts andmedia
with antibody to ER-TR7 and a-smooth muscle actin (a-SMA)
(Figure 2D). In control mice, a thin layer of ER-TR7+ cells marked
the adventitia, whereas the media uniformly expressed a-SMA
(Figure 2D). However, 8 weeks after Smad4 deletion, the ER-
TR7+ cells were detected in the thickened adventitia (asterisk
in Figure 2D) and were also found among SMCs (arrowheads
in Figure 2D). When alterations of elastic lamellae were more
severe, most cells appeared negative for both a-SMA and
ER-TR7 expression (star in Figure 2D, 16 weeks), whereas
some staining remained at the border of these sites (thick arrows
in Figure 2D, 16 weeks).
8 weeks after Smad4 deletion in SMCs, adventitial inflamma-
tion was clearly present in those regions of the media with frag-
mentation of elastic lamellae. The immune infiltrate (Figure 3A)
was composed mainly of monocyte and macrophages, as indi-
cated by the abundance of CD11b+ (Figure 3B) and CD68+ (Fig-
ure 3C) cells and the near absence of lymphocytes (CD3 staining
in Figure S1I). Adventitial gathering of immune cells was always
found in locations of the media with discrete stacked breaks of
elastic lamellae, indicating a strict association between damage
of the media and the presence of inflammatory infiltrate in the
adventitia. In accordance, flow-cytometric analysis of cells
from aortas isolated 8 weeks after tamoxifen treatment detected
a significantly increased number of infiltrating leukocytes gated
as CD45+ and marked as CD11b+ Ly6Chigh monocytes and
CD11b+ Ly6Clow macrophages (Figures 3D–3I).
Disruption of TGF-b Signaling Induces Early Mechanical
Alterations of the Aorta with No Overt Sign of
Inflammation
Growth of aortic aneurysms is a process typically accompanied
by increased circumferential wall stress (Raaz et al., 2015). Even
though wall stress is usually believed to surge as a conse-
quence of the vessel’s expanding geometry, contributing to
the eventual rupture of advanced aneurysms, it is also conceiv-
able that enhanced circumferential wall stress occurs because
of early biomechanical alterations at pre-aneurysmal stages,
thus contributing to the etiology of the disease itself. On this
note, aortic aneurysms usually display a mechanical behavior
different from that of non-aneurysmal tissue (He and Roach,
1994), and immune response in tissue remodeling participates
in this process (Daugherty and Powell, 2014; Jagadesham
et al., 2008). To find out whether changes in mechanical prop-
erties and recruitment of immune response are early events of
the pathogenetic cascade triggered by Smad4 inactivation
and not a simple consequence of aortic disarrangement
accompanying aneurysm formation, we investigated both me-
chanics and immune response at a time point preceding the
signs of aneurysm formation, i.e., 3 weeks after tamoxifen or
vehicle administration, when aortic diameters measured by ul-
trasound imaging were still comparable between the two
groups (Figure S2A).To test the intrinsic mechanical properties of the aorta after
Smad4 deletion, we excised the ascending portion of the vessel
and mounted it on a pressure myograph. We analyzed the struc-
tural and functional parameters by subjecting vessels to
increasing perfusion pressures. Ascending aorta segments
exhibited increased outer (Figure 4A) and inner (Figure S2B) di-
ameters at increasing perfusion pressure steps. Wall thickness
(Figure S2C) and the wall-to-lumen ratio (Figure 4B) decreased,
reaching statistical significance at low intraluminal pressures.
Although modifications of the above parameters increased
circumferential wall stress (Figure S2D), circumferential strain
(Figure S2E) was comparable between vessels from mutant
and control animals. Relevant to this last observation, the
stress-strain curves showed significantly more aortic stiffness
in Smad4f/f;Myh11-creERT2 mice treated with tamoxifen than
in Smad4f/f;Myh11-creERT2 mice treated with vehicle (Fig-
ure 4C). Accordingly, the incremental elastic modulus, an
intrinsic vessel property independent from the geometry, was
increased at high pressures (Figure 4D). At the microstructural
level, alterations of the vessel wall were detectable as well, as
surmised by the presence of elastic lamellae breaks even
3 weeks after Smad4 deletion (Figures 4E–4G).
The above data clearly show thatmodifications of themechan-
ical properties of the aorta are an early event in aneurysm forma-
tion, suggesting that Smad4 inactivation could impinge on the
expression of genes relevant for structural stability and functional
performance of the vessel. Given that Smad-dependent TGF-b
signaling has been identified as a major determinant of differen-
tiation and functional phenotype of SMCs, aswell as extracellular
matrix (ECM) setup and cell adhesion (Guo and Chen, 2012), we
performed analyses on genes involved in these functions. The
expression of several cytoskeletal genes was similar between
Smad4f/f;Myh11-creERT2mice treatedwith tamoxifen and those
treated with vehicle (Figure S2F). Moreover, the phosphorylation
of MLC20 andMYPT1, major regulators of SMC contractility and
calcium sensitivity, respectively, was also comparable between
the two groups (Figure S2G). On the other hand, investigation
of genes involved in the ECM and cell adhesion revealed some
differences. Among numerous genes analyzed, expression of
the following six genes varied significantly between control
mice and mice with a Smad4 deletion: Eln, Col1a1, Lox (ECM
and its metabolism), Itga2 (collagen receptor), and Pxl and Vcl
(focal adhesion components) (Figure S2H). However, no changes
in the transcripts of different proteases were noted (Figure S2I).
Smad4 Signaling Negatively Regulates IL-1b Production
in SMCs
In addition, analysis of several cytokines and chemokines
revealed that the inactivation of Smad4 increased SMC tran-
scripts of IL-1b, IL-6, and CCL2 while reducing those of IL-4,
CXCL10, interferon-g (IFN-g), and IFN-b (Figure 5A). It is worth
noting that the observed changes were most likely related to
genes expressed in SMCs of the media, given that the adventitia
was carefully removed. On the other hand, this was not surpris-
ing because it is well known that IL-1b, despite being produced
at high concentrations in stimulated macrophages, was found to
be upregulated also in aortic SMCs in human thoracic aneu-
rysms (Johnston et al., 2014). IL-1b is produced and stored in
cells as an inactive precursor, and the release in its active formImmunity 47, 959–973, November 21, 2017 963
Figure 3. Smad4 Deficiency in SMCs Determines a Progressive Recruitment of Monocytes and Macrophages in the Aortic Wall
(A–C) Sections from the ascending aortas of Smad4-SMCiko and Smad4-SMCWT mice 8 weeks after tamoxifen treatment were stained with different hemato-
poietic cell markers. Strong staining for CD11b (B) and CD68 (C) indicates that most adventitial cells of hematopoietic origin (CD45) (A) are monocytes and
macrophages. Scale bars, 50 mm.
(D–I) Flow-cytometric gating in Smad4-SMCiko (E) and Smad4-SMCWT (D) mice and quantification of aortic leukocytes (F–I). n = 6 Smad4-SMCWT mice and 8
Smad4-SMCiko mice. Student’s t test for independent samples: (F) t(8.780) =2.639, (G) t(8.333) =3.246, (H) t(8.735) =3.505, and (I) t(8.834) =3.095; *p < 0.05 and
**p < 0.01.
Please also see Figures S1I and S7C.
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Figure 4. Alterations of Biomechanical Functions of the Aorta Precede the Appearance of Aneurysm
(A–D) Segments of ascending aorta were dissected 3 weeks after Smad4 deletion, mounted on a pressure myograph, and subjected to increasing perfusion
pressure for determining the following parameters: outer diameter (A), wall-to-lumen ratio (B), stress-strain relationship showing aortic stiffness (C), and incre-
mental young elastic modulus (D). n = 11 Smad4-SMCWTmice and 7Smad4-SMCikomice. Two-way ANOVA for repeatedmeasures: (A) df = 5, F(interaction) = 5.763;
(B) df = 5, F(interaction) = 3.773; and (D) df = 3, F(interaction) = 5.775. Dashed lines in (C) represent the slopes of stress-strain curves, and their differences were tested
by linear regression analysis (df = 1, F(interaction) = 13.671). *p < 0.05, **p < 0.01, ***p < 0.001.
(E and F) Staining of consecutive sections of ascending aorta with Weigert reagent (E) or H&E (F). Elastic lamellae breaks started to appear 3 weeks after Smad4
deletion. Scale bars, 50 mm.
(G) Quantitation of breaks of elastic lamellae in ascending aorta: n = 7 Smad4-SMCWTmice 9 Smad4-SMCiko mice. Mann-Whitney test for independent samples:
*p < 0.05.
Please also see Figure S2.requires caspase-1 cleavage. In turn, in order to be activated,
caspase-1 requires the function of NLRP3, a sensor that is an
essential component of the NLRP3 inflammasome, a multipro-
tein platform that assembles in response to infection and tissue
damage to allow the activation of inflammatory caspases
(Schroder and Tschopp, 2010). Therefore, we tested NLRP3
mRNA amounts and found them to be significantly higher in
Smad4f/f;Myh11-creERT2 mice treated with tamoxifen than in
control mice (Smad4f/f;Myh11-creERT2 mice treated withvehicle) (Figure 5A). When we looked for infiltrating immune cells
by flow-cytometric analysis 3 weeks after tamoxifen, we did not
find increased CD45+ leukocytes or, more specifically, CD11b+
monocytes (Figures S3A–S3D), suggesting that immune reaction
surged later and further supporting the concept that IL-1b should
be activated in SMCs as a danger signal.
To provide additional evidence that deletion of Smad4 in
SMCs determined an upregulation of IL-1b in a cell-autonomous
way, we analyzed and quantified by confocal microscopy theImmunity 47, 959–973, November 21, 2017 965
Figure 5. Smad4 Ablation in SMCs Activates Inflammation Early in the Media and Induces IL-1b Production
(A) Ascending aortas were collected 3 weeks after tamoxifen or vehicle administration, the adventitia was carefully removed, and the media were processed for
RNA purification and qRT-PCR analysis. Analysis of several cytokine and chemokine gene transcripts showed significant variation for those encoding IL-1b, IL-6,
and CCL2 (upregulated) and those encoding IL-4, CXCL10, IFN-g, and IFN-b (downregulated). Transcripts of the inflammasome component NLRP3 were also
(legend continued on next page)
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percentage of IL-1b immunofluorescence in the SMC area
labeled with a-SMA (Figures 5B–5D). Similarly, flow-cytometric
analysis of single-cell suspensions prepared from the aortas of
Smad4f/f;Myh11-creERT2 mice treated with tamoxifen and
Smad4f/f;Myh11-creERT2 mice treated with vehicle revealed
that the inhibition of TGF-b signaling increased the percentage
of IL-1b+ cells specifically in the SMC fraction, obtained by
gating of CD45CD31 and a-SMA+ cells (Figures 5E–5J).
We next looked at themechanisms responsible for the upregu-
lation of IL-1b in SMCs, determined by the deletion of Smad4. As
first, we assessed the possibility that IL-1b could be directly
upregulated in SMCs and, to this aim, exploited a typical pro-in-
flammatory stimulus known to regulate the expression of this
cytokine, namely lipopolysaccharide (LPS), the bacterial endo-
toxin activating Toll-like receptor 4 (TLR4). The in vitro stimulation
ofSMCswith LPSstrongly upregulated themRNAamounts of the
main cytokines thatwe found upregulated in the vessels deficient
inSmad4 signaling anddeprived of the adventia layer: IL-1b, IL-6,
and CCL2 (Figures S3E–S3G). To unravel the specific role of
TGF-b signaling in modulating IL-1b production in SMCs in the
more complex context of whole aortic tissue, we directly stimu-
lated pressurized vessels with LPS in the presence or absence
of TGF-b and assessed IL-1b-producing cells by flow cytometry.
As shown in Figures S3H and S3I, the percentage of IL-1b+ cells
on SMCgatingwas significantly increased upon LPS stimulation.
The concomitant incubation of vessels with TGF-b significantly
hampered the LPS-mediated IL-1b production, whereas TGF-b
alone had no significant effect (Figures S3H and S3I). Similar
results were obtained when vessels were incubated with the
sameprotocol and analyzed by confocalmicroscopy after immu-
nofluorescence staining (Figures S3J and S3K).
Together, these data suggest to us that, in principle, TGF-b
signaling in SMCs is able to negatively regulate IL-1bwhen chal-
lenged by stimuli such as LPS. To put this observation in the
context of the phenotype observed in Smad4f/f;Myh11-creERT2
mice treated with tamoxifen, we attempted to mimic the effect of
genetic deletion of Smad4 in the simpler experimental system of
pressurized isolated vessels. When aortas from wild-type mice
were incubated with the TGF-bRI inhibitor SB525334, IL-1b
was markedly increased in SMCs (Figures S4A–S4C), thus
supporting the concept that TGF-b signaling through Smad4
directly acts as an inhibitor of IL-1b.
IL-1b Activates an Autocrine Pathway in SMCs with a
Central Role in the Aortic Pathology of Mice with
Inducible Smad4 Deletion in SMCs
Smad4 inactivation is expected to block the transcriptional
response stimulated by the canonical TGF-b and bone morpho-increased. Student’s t test for independent samples (n = 3–8mice) was applied for
(t(8) = 2.734). A Mann-Whitney test for independent samples was applied for Il1b
(B–D) Representative images of IL-1b immunofluorescent staining in ascending a
bars, 20 mm. Staining was quantified as the relative fluorescence intensity norma
test for independent samples: *p < 0.05.
(E–J) Aortic cell suspensions from the aortas of Smad4-SMCWT (E) and Smad4-S
IL-1b antibodies or an appropriate isotype control and assessed by flow cytom
SMCiko) of hematopoietic (CD45+CD11b+) cells, nonhematopoietic vascular cel
sponding isotype control for IL-1b (light blue) within each gate is shown. The perce
group. Student’s t test for independent samples: Mo-Mac (G, ns), fibroblasts (H,
Please also see Figures S3, S4, and S7D–S7F.genetic protein (BMP) pathways. However, in the absence of
Smad4, TGF-b receptors remain functionally intact and continue
to signal through other paths collectively referred to as non-
Smad (non-canonical) signaling (Mu et al., 2012). These path-
ways are considered to be of pathogenetic importance for aortic
aneurysms with dysregulation of TGF-b signaling, such as those
found in Marfan syndrome and LDS. We therefore analyzed the
phosphorylation of kinases and regulatory Smads that might
take part in non-canonical TGF-b signaling. Silenced
Smad4 was accompanied by increased phosphorylation of
Smad2/3 and Smad1/5/8 (Figures S4D and S4E). However,
expression of TGF-b and BMP target genes was not affected
(Figure S4F). Moreover, except for Smad4 transcript reduction,
no variations were detected for other components of the two
pathways (Figures S4G and S4H). More important, amounts of
phosphorylated Erk1/2, p38, and JNKmitogen-activated protein
kinase (MAPK) (Figures S4I and S4J) and PKB, also referred to as
Akt (data not shown), remained unaltered, thus ruling out the
activation of these non-canonical TGF-b pathways. We also
tested activation of TGF-b-activated kinase 1 (TAK-1), another
MAPK whose activation by TGF-b does not require kinase activ-
ity of TGF-b receptors (Mu et al., 2012). Although we found no
variation in TAK-1 phosphorylation (Figures S4K and S4L), to
our surprise, we detected significantly increased phosphoryla-
tion of a potential downstream signaling component, NF-kB,
specifically the RelA subunit, also known as p65 (Figures S4K
and S4L). NF-kB is a transcriptional complex regulated by stimuli
such as various types of stress, and it controls a large variety of
target genes, several of which are involved in inflammation
(Hayden and Ghosh, 2012). Thus, the increase in P-RelA in
SMCs indicates that NF-kBmight contribute to the aortic pheno-
type of Smad4 mutants by inducing modification of the expres-
sion of several cytokines and chemokines (Figure 5A). In turn,
some inflammatory cytokines, including IL-1b, have been
reported to affect collagen biosynthesis in various types of
SMCs (Amento et al., 1991; Aoki et al., 2009), thus suggesting
that the early mechanical alterations of the vessel and later
concomitant recruitment of immune response could be two
sides of the same phenomenon—a molecular mechanism acti-
vated by Smad4 deletion.
The above results suggest that NF-kB and IL-1b might be
involved in aneurysm formation due to Smad4 deletion in
SMCs. IL-1b can be induced by NF-kB, but it is also an activator
of NF-kB (Hiscott et al., 1993; Weber et al., 2010), hinting at the
possibility that positive feedback between the two components
might aggravate aneurysm progression. In relation to this issue,
we assessed the expression of IL-1 receptor (IL-1R) in the aortas
of Smad4f/f;Myh11-creERT2 mice treated with vehicle orIl4 (t(8) = 3.835),Cxcl12 (not significant [ns]),Ccl5 (ns), Ifng (t(8) = 2.302), and Ifnb
, Nlrp3, Il6, Il18, Il10, Ccl2, Cxcl10, and Tnf.
ortas of Smad4-SMCWT (n = 5) (B) and Smad4-SMCiko (n = 6) (C) mice. Scale
lized to the media layer area and identified as a-SMA+ cells (D). Mann-Whitney
MCiko (F) mice were stained with anti-CD45, CD11b, CD31, a-SMA, CD29, and
etry. Representative IL-1b staining (red Smad4-SMCWT and blue for Smad4-
ls, gated endothelial cells (ECs), fibroblasts, and SMCs is shown. The corre-
ntage of IL-1b positivity within each subset was quantified (G–J). n = 4mice per
ns), ECs (I, ns), and SMCs (J, t(6) = 2.860); *p < 0.05.
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Figure 6. Inhibition of the IL-1b-CCL2 Axis Hampers Progression of Aortic Aneurysm in Mice with SMC-Specific Smad4 Deletion
(A and B) Representative ultrasound imaging of the ascending (A) and abdominal (B) aortas of Smad4-SMCiko and Smad4-SMCiko;Il1r1/mice shows significant
protection from vessel dilation and aneurysm formation in mice with an Il1r1-null background. Scale bars, 1 mm.
(legend continued on next page)
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tamoxifen and found a strong colocalization in SMCs (Figures
S5A and S5B). Supporting the hypothesis of an autocrine mech-
anism regulated by positive feedback of IL-1b in SMCs, we found
that direct stimulation of SMCs with IL-1b was able to increase
the expression of the cytokine itself (Figure S5C). In the same
setting, IL-1b stimulation was also able to increase the expres-
sion of Il6 and the chemokine Ccl2 in SMCs (Figures S5D and
S5E), suggesting an apical role of IL-1b signaling in inflammation
and activation of the immune response.
Therefore, we reasoned that blocking IL-1R might dampen
IL-1b signaling and have a beneficial effect on morphological
alterations of aneurysms. We tested this hypothesis by inducing
Smad4 deletion in SMCs of mice with an Il1r1-null background
(Smad4f/f;Myh11-creERT2;Il1r1/mice treated with tamoxifen).
Serial ultrasonographic analyses revealed that ablation of Il1r1
protected from pathology progression in the ascending aorta
and the abdominal part (Figures 6A–6D). Further supporting
the protective role of IL-1 inhibition, Kaplan-Meier analysis
showed that Il1r1 ablation increased survival of Smad4f/f;
Myh11-creERT2;Il1r1/mice treatedwith tamoxifen (Figure 6E).
Overall, these results suggest that increased IL-1 signaling is a
central event following Smad4 inactivation.
We next tested whether the increase in P-RelA was due to
activation of the IL-1 pathway or was independent from it. RelA
phosphorylation was analyzed by immunoblotting in the aortas
of tamoxifen-treated Smad4f/f;Myh11-creERT2 mice with or
without the Il1r1-null mutation. P-RelA was significantly more in-
hibited in tamoxifen-treated Smad4f/f;Myh11-creERT2 mice car-
rying the Il1r1/ mutation than in tamoxifen-treated Smad4f/f;
Myh11-creERT2 mice without the mutation (Figures S5F and
S5G), suggesting that NF-kBactivation in themedia is dependent
on IL-1b signalingandnotviceversa. Inaddition,we found that the
increased expression of Ccl2 andNlrp3 in the aortas of Smad4f/f;
Myh11-creERT2mice treated with tamoxifen was rescued in the
Il1r1/ background, whereas the reduced expression of Il4,
Ifnb, and Ifng transcriptswasnormalized (FigureS5H), suggesting
that these genes were downstream of IL-1b. Deletion of Il1r1 also
brought transcripts for Eln, Col1a1, Lox, Itga2, Pxn, and Vcl back
to normal amounts (FigureS5H). Thus far, these data suggest that
IL-1b has a key role not only in the control of cytokines that deter-
mine inflammation but also in the expression of genes important
for ECM stability and cell adhesion. Further supporting this last
observation, we also found that tamoxifen-treated Smad4f/f;
Myh11-creERT2 mice on the Il1r1/ background were signifi-
cantly protected from the progressive break of elastic lamellae
that occurred in Smad4f/f;Myh11-creERT2 mice treated with
tamoxifen (Figures S5I and S5J).
To appreciate fully the pathophysiological impact of IL-1b tar-
geting on the aortic disease, we assessed in vivo mechanical(C and D) Ascending (C) and abdominal (D) aortic diameters were quantitatively
repeated measures: df = 4; F(interaction) = 23.82 (ascending aorta) and 16.03 (abd
(E) Kaplan-Meier plot for Smad4-SMCiko (n = 17) and Smad4-SMCiko;Il1r1/ (n =
deletion. Log rank test: df = 1, c2 = 24.72, p < 0.0001.
(F and G) Representative ultrasound imaging of the ascending (F) and abdominal (
shows significant protection from vessel dilation and aneurysm progression in m
(H and I) Quantitative analysis of ascending (H) and abdominal (I) aortic diameters.
aorta) and 19.90 (abdominal aorta); *p < 0.05, **p < 0.01, ***p < 0.001.
Please also see Figure S5 and S6.properties by echo-tracking the wall motion on ultrasound
images. We extracted data relative to arterial stiffness and
distensibility. Smad4f/f;Myh11-creERT2 mice treated with
tamoxifen showed a significantly increased index of arterial stiff-
ness, which was already evident 4 weeks after gene inactivation
and continued to worsen at the last time point (Figure S5K). At
the same time, Smad4f/f;Myh11-creERT2 mice treated with
tamoxifen displayed less distensibility of the aorta than mice
treated with vehicle (Figure S5L). The inhibition of IL-1b signaling,
obtained in tamoxifen-treated Smad4f/f;Myh11-creERT2 mice
with the Il1r1/ mutation, realized complete protection from
the mechanical alterations observed in Smad4f/f;Myh11-
creERT2 mice treated with tamoxifen (Figures S5K and S5L).
These results appear particularly important because they further
support a protective effect of IL-1b inhibition on pathology pro-
gression in Smad4f/f;Myh11-creERT2;Il1r1/ mice treated with
tamoxifen, despite themoderately increased aortic diameter dis-
played with time progression (Figures 6A–6D).
Inhibition of the CCL2-CCR2 Chemokine Axis Blocks
Pro-inflammatoryMonocyte Infiltration and Ameliorates
Aneurysm Progression
The fact that IL-1b was upregulated before infiltration of mono-
cytes and macrophages (Figures 5A and S3A–S3D) suggests
that this cytokine plays a role in transferring signals from the
aortic walls to the immune system, which is later activated. On
the other hand, IL-1b was able to induce the expression of
Ccl2 in SMCs (Figure S5E), and the peaking of Ccl2 observed
3 weeks after tamoxifen treatment in Smad4f/f;Myh11-creERT2
mice was rescued when the deletion of Smad4 was induced in
mice with IL-1R deficiency (Figure S5H). Given that Ly6Chigh
pro-inflammatory monocytes typically express high amounts of
CCR2 (a receptor of CCL2), we hypothesized that the migration
of this subset of monocytes, later found infiltrated in the aortic
walls of Smad4f/f;Myh11-creERT2 mice treated with tamoxifen,
could be regulated through this pathway. Thus, we generated
another murine model to induce the ablation of Smad4
in SMCs of CCR2-deficient mice (Smad4f/f;Myh11-
creERT2;Ccr2/ mice treated with tamoxifen), thus making
them unable to respond to CCL2-induced migration of Ly6Chigh
pro-inflammatory monocytes. Resembling Smad4f/f;Myh11-
creERT2;Il1r1/ mice treated with tamoxifen, Smad4f/f;
Myh11-creERT2;Ccr2/ mice treated with tamoxifen displayed
a slower progression of aortic aneurysm with a significantly
reduced diameter both in the ascending and in the abdominal
tracts (Figures 6F–6I). However, unlike tamoxifen-treated
Smad4f/f;Myh11-creERT2;Il1r1/ mice that manifested early
protection from structural damage in the aorta (Figure S5I),
Smad4f/f;Myh11-creERT2;Ccr2/ mice treated with tamoxifenanalyzed by ultrasound imaging (n = 9 mice per group). Two-way ANOVA for
ominal aorta).
17) mice shows that IL-1 inhibition significantly reduced mortality after Smad4
G) aortas of Smad4-SMCiko and Smad4-SMCiko;Ccr2/mice (n = 5 per group)
ice with a Ccr2-null background. Scale bars, 1 mm.
Two-way ANOVA for repeated measures: df = 4; F(interaction) = 8.929 (ascending
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started to display the breaks in the elastic lamellae of the vessels
3 weeks after the deletion of Smad4 (Figure S6A). Together,
these observations suggest that the initial damage in the elastic
lamellae of the aorta, despite relying on the activation of IL-1b,
was independent from the infiltration of inflammatory monocytes
recruited through the downstream activation of CCL2. This
conclusion is also in line with the additional evidence showing
that early upregulation of IL-1b in SMCs was still observed in
mice where deletion of Smad4 was induced in a CCR2-deficient
background (Figures S6B–S6D).
We also analyzed the infiltrating immune cells at 8 weeks,
when aortas from Smad4f/f;Myh11-creERT2 mice treated with
tamoxifen were densely enriched with monocytes and macro-
phages (Figure 3), and found a significant reduction of
Ly6Chigh pro-inflammatory monocytes in Smad4f/f;Myh11-
creERT2;Ccr2/ mice treated with tamoxifen, despite the still
increased number of Ly6ClowF4/80hi macrophages (Figures
S6E–S6H). These results show that the recruitment of classical
pro-inflammatory monocytes, depending on the CCL2 signaling,
was efficiently blocked by CCR2 inactivation, whereas mobiliza-
tion of intermediate monocytes and non-classical macrophages
was not completely compromised, given that it typically does not
rely on the CCL2-CCR2 axis.
Therapeutically Targeting IL-1b Signaling Improves
Aortic Pathology in Smad4f/f;Myh11-creERT2 Mice
Treated with Tamoxifen
To test the translational potential of our findings, we neutralized
IL-1b signaling with the clinically relevant murine version of the
FDA-approved clinical drug canakinumab. After tamoxifen
administration, used to induce SMC deletion of Smad4, treat-
ment with anti-IL-1b or control immunoglobulin (CTRL IgG)
began and was repeated every week. During a time course of
16 weeks, whereas administration of CTRL IgG did not change
aneurysm progression, treatment with anti-IL-1b antibody signif-
icantly hampered aneurysm formation in both ascending and
abdominal tracts of the aorta (Figures 7A–7D). The above data
not only add support to the mechanistic role of IL-1b in the aortic
pathology induced by SMC deletion of Smad4 but also identify
treatment with IL-1b inhibitors as potential pharmacological ther-
apy of the disease.
DISCUSSION
Pieces of literature consistently associate disrupted TGF-b
signaling with the development of aortic aneurysms. Yet, the
molecular mechanisms mediating this association remain to be
identified. Our results provide evidence that IL-1b has an impor-
tant role in triggering aneurysm formation in a model of aortop-
athy induced by postnatal deletion of Smad4 in SMCs. Indeed,
we found that genetic inhibition of the IL-1b pathway significantly
hampered progression of aneurysms in Smad4f/f;Myh11-
creERT2 mice treated with tamoxifen. More important, blocking
IL-1 signaling in Smad4f/f;Myh11-creERT2 mice treated with
tamoxifen reduced the rate of death by aneurysm rupture. To
highlight the potential translational use of IL-1 pathway inhibi-
tors, we selectively neutralized IL-1b with the murine version of
an antibody that has recently emerged as an effective treatment
for secondary prevention of cardiovascular events in the large-970 Immunity 47, 959–973, November 21, 2017scale clinical trial CANTOS (Ridker et al., 2017). The results
showed a significant protection from aneurysm progression in
both ascending and abdominal aorta, hence opening the door
to translational perspectives for limiting aortic Smad4-depen-
dent aneurysm pathology with an already clinically approved
drug. This adds to the protective role of IL-1b inhibition previ-
ously described in experimentally induced cerebral arterial,
abdominal aortic, and thoracic aortic aneurysms (Johnston
et al., 2014; Johnston et al., 2013; Moriwaki et al., 2006).
Our data show that Smad4 is required in SMCs for the mainte-
nance of normal aortic structure and function. In particular, we
provide evidence that downregulation of Smad4 stimulates
IL-1b expression in SMCs and that this cytokine regulates the
function of several other genes, including those encoding other
cytokines and chemokines and components of the ECM and
its metabolism and focal adhesions.
The finding that that expression of other cytokines is normal-
ized in the Il1r1/ background indicates that IL-1b is instru-
mental for the altered expression of cytokines and chemokines
observed in the media early after the induction of Smad4 inacti-
vation. Among upregulated cytokines and chemokines, CCL2
carries out the relevant function of macrophage recruitment, as
previously suggested (Zhang et al., 2016). Relevant to this point,
the deletion of Smad4 in SMCs of mice with CCR2 deficiency
provoked a milder progression of aortic aneurysm with a signif-
icantly reduced diameter both in the ascending and in the
abdominal tracts of the aorta, thus unravelling a crucial role of
CCL2-induced migration of Ly6Chigh pro-inflammatory mono-
cytes in the aortic pathology of Smad4f/f;Myh11-creERT2 mice
treated with tamoxifen. Once recruited into the adventitia, the
inflammatory infiltrate of monocytes and macrophages progres-
sively spreads into the media and consequently disrupts this
layer’s structure and aneurysm enlargement and rupture. In
addition, an increased number of LyC6lowF4/80high monocytes
and macrophages have been detected in the aorta. The function
of this cell population was not addressed in this study, but their
presence could represent a tissue-reparative response to coun-
terbalance the pro-inflammatory burden.
Although the axis dependent on IL-1b and CCL2 is key to
aneurysm development, we detected modifications of aortic
mechanical properties before any sign of inflammatory cell infil-
tration into the vessel wall, indicating that an early contribution to
dilation could come from changes of the composition or struc-
tural organization of the media, possibly derived from the
observed downregulation of genes such as Eln, Col1a1, Lox,
Itga2, Pxn, and Vcl. Our results suggest that IL-1b is key not
only for inflammation but also for regulation of the genes involved
in ECM stabilization and cell adhesion.
Abnormal modulation of signaling pathways has been
reported in different aneurysm models (Aoki et al., 2007; Gillis
et al., 2013). Among the various analyzed, we obtained evidence
of NF-kB activation, specifically a substantial increase in phos-
phorylation of the RelA subunit. Considering the cross-talk
between IL-1b and NF-kB, it was relevant to determine which
component could activate the other. By analyzing aortas at a
time after Smad4 inactivation when IL-1b expression was
increased only in SMCs and not in fibroblasts or hematopoietic
cells, we found that the increase in RelA phosphorylation was
abolished in mice with the Il1r1-null background. This result
Figure 7. Therapeutically Targeting IL-1b Improves the Aortic Pathology and Aneurysm Dilation Induced by SMC-Specific Smad4 Inacti-
vation
Compared with treatment with a non-relevant IgG, neutralizing IL-1b significantly attenuates aneurysm progression in the ascending (A) and abdominal (B) aortas
of Smad4-SMCiko mice (scale bars, 1 mm). Ascending (C) and abdominal (D) aortic diameters were quantitatively analyzed by ultrasound imaging. n = 7 Smad4-
SMCiko mice treated with CTRL IgG and 6 Smad4-SMCiko mice treated with anti-IL-1b. Two-way ANOVA for repeated measures: df = 4; F(interaction) = 9.505
(ascending aorta) and 8.863 (abdominal aorta); *p < 0.05, **p < 0.01, ***p < 0.001.excludes that NF-kB activation is the primary effect of Smad4
loss of function. Instead, it appears that Smad4 deletion
unlashes IL-1b production and activation by SMCs, and this
stimulates NF-kB signaling that in turn sustains IL-1b expression
in SMCs.
The relevant finding that IL-1b production was stimulated only
in SMCs early after Smad4 inactivation also allows interpretation
of the observation that tissue damage, assessed as breaks of
elastic lamellae, was substantially reduced by inactivation of
the IL-1 receptor. In fact, this implies that damage is secondary
to IL-1b activation and not a primary effect of Smad4 deletion
driving production of damage effectors such as IL-1b.
Of note, although IL-1b inhibition remarkably ameliorated
aneurysm progression, it did not produce complete rescue, sug-
gesting that other factors might be involved in this pathology. We
can only hypothesize two tiers of alternative regulation of aneu-rysm formation: the first depends on a group of molecules that
are under the strict control of TGF-b signaling and whose targets
were not exhaustively investigated in our study; the second com-
prises signaling molecules that act in parallel with IL-1b, such as
IL-1a and IL-18. The former shares the same receptor with IL-1b
but does not require activation, whereas the latter acts through a
different receptor but is activated similarly to IL-1b (Garlanda
et al., 2013).
Our study focused on the identification of signaling pathways
dysregulated by Smad4 at initial stages of aortic pathology and
spotted the important role of IL-1b. However, aneurysm is the
outcome of a complex process in which more downstream com-
ponents of the IL-1b cascade (and other cytokines) might play a
similarly relevant role. This could be the case with proteases,
whose function has been reported to be either protective or
aggravating depending on the aneurysm’s location (thoracic orImmunity 47, 959–973, November 21, 2017 971
abdominal) and the experimental model used (Alexander et al.,
2012; Deguchi et al., 2009; Longo et al., 2002; Martı´n-Alonso
et al., 2015; Shen et al., 2015). In the present context, the orches-
tration of the activity of proteases from different cellular sources
could determine early breaks of elastic lamellae of the media
and, later on, the systematic attack of adventitial inflammatory
infiltrates from the outer media inward.
In summary, given the SMC-specific recombination in adult
animals, we could hypothesize the initial steps of aneurysm
development induced by Smad4 inactivation as follows: (1)
loss of Smad4 function induces IL-1b expression and activation
in SMCs; (2) modulation of CCL2 expression stimulates mono-
cyte recruitment and inflammation in the adventitia; (3) IL-1b
also activates NF-kB in SMCs to sustain IL-1b production, es-
tablishing an autocrine mechanism further stimulating the
recruitment of innate immune response; (4) in parallel, IL-1b
modifies the expression of specific SMC genes relevant for
ECM composition or metabolism and cell adhesion, thus altering
the mechanical properties of the arterial wall and vessel diam-
eter; and (5) all these factors contribute to the development of
the aortic aneurysm.
The above pathogenetic scheme highlights the central role of
IL-1b in aneurysmal pathology induced by dysregulated TGF-b
canonical signaling and indicates this cytokine as an initial target
for medical treatment of aneurysms in patients with SMAD4
mutations.
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Antibodies
Mouse anti-a-SMA for immunohistochemistry or
immunofluorescence
Sigma Aldrich A5228; RRID: AB_262054
Rabbit anti-Collagen I for immunohistochemistry or
immunofluorescence
Acris R1038; RRID: AB_978381
Rabbit anti-IL1 beta for immunohistochemistry or
immunofluorescence
Genetex GTX74034; RRID: AB_378141
Rabbit anti-IL1 Receptor I for immunohistochemistry or
immunofluorescence
Abcam ab106278; RRID: AB_10865509
Rabbit anti-Smad4 for immunohistochemistry or
immunofluorescence
Santa Cruz sc-7154; RRID: AB_2302322
Rat anti-CD11b for immunohistochemistry or
immunofluorescence
Abd Serotec MCA711G; RRID: AB_323167
Rat anti-CD3 for immunohistochemistry or
immunofluorescence
eBioscience 17-0032; RRID: AB_10597589
Rat anti-CD45 for immunohistochemistry or
immunofluorescence
Abd Serotec MCA 1388; RRID: AB_321729
Rat anti-CD68 for immunohistochemistry or
immunofluorescence
Abd Serotec MCA 1957GA; RRID: AB_324217
Rat anti-ER-TR7 for immunohistochemistry or
immunofluorescence
Santa Cruz sc-73355; RRID: AB_1122890
Goat anti-Myh11 for western blot Santa Cruz sc-79079; RRID: AB_3231672147150
Mouse anti-Smad4 for western blot Santa Cruz sc-7966; RRID: AB_2184015
Mouse anti-b-actin for western blot Sigma Aldrich A5316; RRID: AB_476743
Rabbit anti P-ERK 1/2 for western blot Santa Cruz sc-101760; RRID: AB_2139987
Rabbit anti P-TAK1 for western blot Cell Signaling 4531; RRID: AB_390772
Rabbit anti-MLC20 for western blot Santa Cruz sc-376606; RRID: AB_11150665
Rabbit anti-P-(S536) RelA/p65 for western blot Cell Signaling 3033; RRID: AB_331284
Rabbit anti-P-JNK for western blot Cell Signaling 9251; RRID: AB_331659
Rabbit anti-P-MLC20 for western blot Cell Signaling 3671P; RRID: AB_330248
Rabbit anti-P-MYPT1 for western blot Santa Cruz sc-17556; RRID: AB_653348
Rabbit anti-P-p38 for western blot Cell Signaling 9215; RRID: AB_331762
Rabbit anti-P-Smad1/5/8 for western blot Merck Millipore AB3848; RRID: AB_177439
Rabbit anti-P-Smad2 for western blot Cell Signaling 3101; RRID: AB_331673
Rabbit anti-RelA/p65 for western blot Santa Cruz sc-372; RRID: AB_632037
Rabbit anti-TAK1 for western blot Bethyl A301-915A; RRID: AB_1524082
Alexa488 anti-mouse, secondary antibody Jackson Immunoresearch 715-545-150; RRID: AB_2340846
Cy3 anti-rabbit, secondary antibody Jackson Immunoresearch 111-165-003; RRID: AB_2338000
Cy3 anti-rat, secondary antibody Jackson Immunoresearch 112-165-167; RRID: AB_2338251
HRP anti-mouse, secondary antibody Bethyl A90-116P; RRID: AB_67183
HRP anti-rabbit, secondary antibody Bethyl A120-101P; RRID: AB_67264
BUV395 CD45 (clone 30-F11) for flow cytometry BD Horizon 564279; RRID: AB_2651134
BUV737 CD11b (clone M1/70) for flow cytometry BD Horizon 564443
BV421-Ly6C (clone AL-21) for flow cytometry BD Horizon 562727
BV510-F4/80 (clone BM8) for flow cytometry Biolegend 123135; RRID: AB_2562622
BV605-CD29 (clone HM b 1-1) for flow cytometry BD OptiBuild 740365
BV711-CD31 (clone MEC 13.3) for flow cytometry BD OptiBuild 740680
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CD16/CD32 (clone 2.4G2) for flow cytometry BD PharMingen 553141; RRID: AB_394656
FITC-aSMA (clone 1A4) for flow cytometry Abcam ab8211; RRID: AB_306359
PE CD19 (clone 1D3) for flow cytometry BD PharMingen 553786; RRID: AB_395050
PE CD45R/B220 (cloneRA3-6B2) for flow cytometry BD PharMingen 553090; RRID: AB_394620
PE CD49b (clone DX5) for flow cytometry BD PharMingen 553858; RRID: AB_395094
PE CD90.2 (clone 53-2.1) for flow cytometry BD PharMingen 553006; RRID: AB_394545
PE IgG2B (clone 141945) for flow cytometry R&D Systems IC013P; RRID: AB_357259
PE IL-1b (clone 166931) for flow cytometry R&D Systems IC4013P; RRID: AB_10719123
PE Ly6G (clone 1A8) for flow cytometry BD PharMingen 551461; RRID: AB_394208
PE NK1.1 (clone PK136) for flow cytometry BD PharMingen 553165; RRID: AB_394677
PE Ter-119 (clone TER-119) for flow cytometry BD PharMingen 553673; RRID: AB_394986
In vivo mouse anti-mouse IL-1b IgG2a/k Novartis N/A
In vivo mouse IgG2a isotype control (C1.18.4) BioXCell BP0085; RRID: AB_1107771
Chemicals, Peptides, and Recombinant Proteins
7-AAD BD PharMingen 559925
Alcian Blue 8GX Sigma Aldrich A5268
Collagenase type I Worthington CLS-1
Collagenase type I Sigma Aldrich C0130
Collagenase type XI Sigma Aldrich C7657
Corn Oil Sigma Aldrich C8267
DAPI Vectashield Vector Laboratories H-1500
Eosin Y Sigma Aldrich 230251
Hematoxylin Invitrogen 51275
Hoechst 33258 Sigma Aldrich 861405
Hoechst 33342 Invitrogen C10338
Hyaluronidase Sigma Aldrich H3506
IL-1b peptide Immunotools 12340013
LiteAblot EXTEND Euroclone EMP013001
LiteAblot PLUS Euroclone EMP011005
Lypopolisaccharide (Salmonella Enterica) Sigma Aldrich L5886
Non-fat dry milk Biorad 170-6404
NuPAGE 10% Bis-Tris Gel Novex NP0301BOX
NuPAGE LDS Sample Buffer Novex NP0007
NuPAGE Sample Reducing Agent Novex NP0009
SB525334 Sigma Aldrich 060916
Tamoxifen Sigma Aldrich T5648
TBS-0.1% Tween20 buffer Sigma Aldrich P7949
TGF-b peptide R&D Systems 7666-MB
Total extraction Kit Merck Millipore 2140
Trizol Invitrogen 15596018
Critical Commercial Assays
Anti-rabbit ELITE VectaStain Kit Vector Laboratories PK-6101; RRID: AB_2336820
cOmplete, EDTA-free Roche 11873580001
Fixation/Permeabilization Kit with GolgiPlug BD Cytofix/Cytoperm Plus 555028
PhosSTOP EASYpack Roche 04906837001
Pierce BCA Protein Assay Kit Thermo Scientific 23227
Experimental Models: Organisms/Strains
Mouse: Smad4f/f Dr. DePinho (Boston) N/A
Mouse: Myh11-creERT2 Dr. Offermanns (Heidelberg) N/A
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Mouse: Il1r1tm1/mx The Jackson Laboratory 028398; RRID: IMSR_JAX:02839
Mouse: Ccr2tm1/fc The Jackson Laboratory 004999; RRID: IMSR_JAX:004999
Mouse: C57BL/6NCrl Charles River N/A
Oligonucleotides
Eln, primers GCTGTGTCACCAGCTGCAG (forward) and
CTCCAAGTCCTGCTCCAGC (reverse)
N/A N/A
Fn1, primers CTGTCAACCTCTGCAGACCTA (forward)
and TTCCTTCCAGCGACCCGTAG (reverse)
N/A N/A
Col1a1, primers GAGCGGAGAGTACTGGATCG (forward)
and GCTTCTTTTCCTTGGGGTTC (reverse)
N/A N/A
Col3a1, primers TCCCATTTGGAGAATGTTGTGCAAT
(forward) and CCAGGAGGCCCAGGGAGA (reverse)
N/A N/A
Tnc, primers TTCGTGTGTTCGCCATCTTGGA (forward)
and ATGATCTCCCATGTTTCGAAAGCA (reverse)
N/A N/A
Thbs1, primers GAACCTCCCAAAATGACCCTAA (forward)
and TACAGACAGGCCTGAGTATCC (reverse)
N/A N/A
Lox, primers CTGCGGAAGAAAACTGCCTG (forward)
and CGTAGCAGTACCCTGTGGTC (reverse)
N/A N/A
Itga1, primers CAATGCCTTGTGTGAAGTTGGA (forward)
and GAAATCCTCCCTTCGGATTGGTG (reverse)
N/A N/A
Itga2, primers ATATTCAGCATTGAAGGCAC (forward)
and GGCTTGTTTAGGAAAGATCAC (reverse)
N/A N/A
Itga5, primers GAACACAAGTTCTGAAATGC (forward)
and ATATACAGCCTCACACTGAAG (reverse)
N/A N/A
ItgaV, primers GACAGTTATTTGGGTTACTCTG (forward)
and GAAAATCCAAAATACGCAGC (reverse)
N/A N/A
Itgb1, primers CCTACAACTCTCTTTCTTCAG (forward)
and CTTTCGTCCATTTTCTCCTG (reverse)
N/A N/A
Itgb3, primers TATAGTGAGCTCATTCCTGG (forward)
and ATTTTCCCGTAAGCATCAAC (reverse)
N/A N/A
Csrp1, primers CCCTGCTACTCCGCCATGTTT (forward)
and TACTTGAAAGTGTGGCTCTCAGC (reverse)
N/A N/A
Csrp2, primers GTCCTCGATGCAACAAGAGAGTG
(forward) and CCTGGGGTCAGGGTCTTGG (reverse)
N/A N/A
Csrp3, primers CAGCACAGACACTGGCGAGC (forward)
and CACATCGTGGGCACTTCTCTG (reverse)
N/A N/A
Tgfb1i1, primers GCCTCTGTGGCTCCTGCAATAAA
(forward) and CTTCTCGAAGAAGCTGCTGCCT (reverse)
N/A N/A
Fhl1, primers GCCCATAAGCGCTGATGCCAAG (forward)
and GGGGTGAAGGCACTTGGCACA (reverse)
N/A N/A
Fhl2, primers CTCGTCCAAGTGCCAGGAATG (forward)
and CTTAGGTATGAAGCTCTTGGTTCC (reverse)
N/A N/A
Zyx, primers GGCTGCTACACCGACACTTTG (forward)
and CTCAGCATGCGGTCAGTGAT (reverse)
N/A N/A
Trip6, primers GAGGTGGGCATGAGCCTCAG (forward)
and GGTGGCTCATGTCATGCACCA (reverse)
N/A N/A
Lpp, primers CCAGTTGTTGCTCCGAAACCC (forward)
and GGAGGAGGAGGGAAGTGTC (reverse)
N/A N/A
Pxn, primers GCTGCCTCAACACCTCAAC (forward) and
GCTGCCTCAACACCTCAAC (reverse)
N/A N/A
Ptk2, primers GCGGACACATGCAGTCTCTG (forward) and
TTGCAACAGCCAAAGCTGGATTC (reverse)
N/A N/A
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Vcl, primers CTGACCAAGTGGCTGACCTC (forward) and
GCTTCCGAGCTGCATTCTCC (reverse)
N/A N/A
Bcar1, primers CGAGGACTGCTTCCTAACCAG (forward)
and GGACGAGAGCAGGCCTTTCT (reverse)
N/A N/A
Abl1, primers GCCAGTGGAGATAACACTCTCA (forward)
and CGTTTGGGCTTCACACCATTC (reverse)
N/A N/A
Il1b, primers ACCTGTGTCTTTCCCGTGGAC (forward) and
GGGAACGTCACACACCAGCA (reverse)
N/A N/A
Nlrp3, primers GGAGAAGGCAGATCATTGG (forward) and
CAGCAAACCATCCACTCTT (reverse)
N/A N/A
Il6, primers ACACTCCTTAGTCCTCGGCCA (forward) and
CACGATTTCCCAGAGAACATGTG (reverse)
N/A N/A
Il18, primers CGAGGATATGACTGATATTGATCAAAG
(forward) and ACTATCCTTCACAGAGAGGGTCA (reverse)
N/A N/A
Il4, primers CACGGATGCGACAAAAATCA (forward)
and CGTTGCTGTGAGGACGTTTG (reverse)
N/A N/A
Il10, primers ATGCTGCCTGCTCTTACTGACTG (forward)
and CCCAAGTAACCCTTAAAGTCCTGC (reverse)
N/A N/A
Ccl2, primers CTTCTGGGCCTGCTGTTCA (forward) and
CCAGCCTACTCATTGGGATCA (reverse)
N/A N/A
Cxcl10, primers ATGACGGGCCAGTGAGAATG (forward)
and TCAACACGTGGGCAGGATAG (reverse)
N/A N/A
Cxcl12, primers CATTGACCCGAAATTAAA (forward) and
CTCTTCTTCTGTCGCTTCT (reverse)
N/A N/A
Ccl5, primers GCAGTCGTGTTTGTCACTCG (forward)
and AGAGCAAGCAATGACAGGGA (reverse)
N/A N/A
Tnf, primers GGCCTCCCTCTCATCAGTTC (forward)
and GTTGTCTTTGAGATCCATGCCG (reverse)
N/A N/A
Ifng, primers AGAGCCAGATTATCTCTTTCTACCTCAG
(forward) and CCTTTTTCGCCTTGCTGTTG (reverse)
N/A N/A
Ifnb, primers GGAGATGACGGAGAAGATGC (forward)
and CCCAGTGCTGGAGAAATTGT (reverse)
N/A N/A
Mmp1, primers GTCTTTGAGGAGGAAGGCGA (forward)
and CAAACCTAGGCCTGGCAGAA (reverse)
N/A N/A
Mmp2, primers TGGAATGCCATCCCTGATAA (forward)
and AGCCCAGCCAGTCTGATTTG (reverse)
N/A N/A
Mmp8, primers ATCCTTGCCCATGCCTTTCAA (forward)
and CCAAATTCATGAGCAGCCAC (reverse)
N/A N/A
Mmp9, primers TTGAAGTCTCAGAAGGTGGAT (forward)
and GCAGGAGGTCGTAGGTCAC (reverse)
N/A N/A
Mmp12, primers AAAGTGGGTTGTAGCATTGC (forward)
and AGAAGGCAGACCAGGACAC (reverse)
N/A N/A
Mmp13, primers GGTCTTCTGGCACACGCTTT (forward)
and CAAGCTCATGGGCAGCAACA (reverse)
N/A N/A
Ctss, primers ATAAAGGCTGTGGAGGCG (forward) and
CATCCGTGGCTTTGTAGG (reverse)
N/A N/A
Tgfb1, primers TTGCTTCAGCTCCACAGAGA (forward)
and TGGTTGTAGAGGGCAAGGAC (reverse)
N/A N/A
Tgfb2, primers CAGCGCTACATCGATAGCAA (forward)
and CCTCGAGCTCTTCGCTTTTA (reverse)
N/A N/A
Tgfb3, primers GATGAGCACATAGCCAAGCA (forward)
and ATTGGGCTGAAAGGTGTGAC (reverse)
N/A N/A
Tgfbr1, primers CCTGGGATTTATAGCAGCAGAC (forward)
and CAGTAACAGTGTATCTATTCAAGTA (reverse)
N/A N/A
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Tgfbr2, primers GAGAAGCCGCATGAAGTCTG (forward)
and GACACACTTGGGAGAAGCGG (reverse)
N/A N/A
Smad2, primers CCAGCAGGAATTGAGCCACA (forward)
and CTGTGTCCATACTTTGGTTCAAC (reverse)
N/A N/A
Smad3, primers GAACACTAACTTCCCTGCTGG (forward)
and CTGCGTCCATGCTGTGGTTC (reverse)
N/A N/A
Smad4, primers GAGCTTGCATTCCAGCCTCC (forward)
and CACAACAGGGCAGCTTGAAGG (reverse)
N/A N/A
Bmp2, primers CAGCCGCGCCAACACCGT (forward) and
CAGATGTGAGAAACTCGTCACTG (reverse)
N/A N/A
Bmp4, primers CGTCCCGCCAGCCGAGC (forward) and
GCCGAGGAGATCACCTCATTC (reverse)
N/A N/A
Bmp6, primers CTCCAGCTGAGTGTGGTGACT (forward)
and GGACCTCGCTCACCTTGAAGA (reverse)
N/A N/A
Alk2, primers CATCACGGCCCAGCTGCC (forward) and
CCACCGAGAGGATGATAAGGC (reverse)
N/A N/A
Alk3, primers GCCCAGATGATGCTATTAATAACAC
(forward) and CAGAGCCTTCATACTTCATACACC (reverse)
N/A N/A
Alk6, primers CCACTCTGCCTCCTCTCAAG (forward)
and CCAAGAGTAAACTACAGACAGTCA (reverse)
N/A N/A
Bmpr2, primers CCTGGATAACCTGAAGCTGCTG
(forward) and CAGCAACTGGACGCTCATCCAA (reverse)
N/A N/A
Acvr2a, primers CTGGCAAGTCTGCAGGTGAC (forward)
and TATCTATCCTCAGAAATGCGTCCC (reverse)
N/A N/A
Acvr2b, primers GTGGCTGTGAAGATCTTCCCAC
(forward) and GGCAGCAATGAACTGCAACAAGTT (reverse)
N/A N/A
Pai1, primers ATGGAGCCTTGACAGTGGG (forward) and
GAGGTCTGGGATGCTGGTT (reverse)
N/A N/A
Ctgf, primers TCCACCCGAGTTACCAATG (forward) and
TAGCCCTGTATGTCTTCACAC (reverse)
N/A N/A
Id1, primers CTGCAGCATGTAATCGACTAC (forward) and
TCGTCGGCTGGAACACATG (reverse)
N/A N/A
Id2, primers AAAACAGCCTGTCGGACCAC (forward) and
CTGGGCACCAGTTCCTTGAG (reverse)
N/A N/A
Id3, primers AGCTTAGCCAGGTGGAAATCCT (forward) and
TCAGCTTGTCTGGATCGGGAG (reverse)
N/A N/A
Acta2, primers GAGAAGCCCAGCCAGTCG (forward) and
CTCTTGCTCTGGGCTTCATC (reverse)
N/A N/A
Myh11, primers CCCAACCCACTCCCAACCT (forward)
and TGCTCTGCTCCGCTCGCTC (reverse)
N/A N/A
Sm22, primers TCCAGTCCACAAACGACCAAG (forward)
and GAATTGAGCCACCTGTTCCATCT (reverse)
N/A N/A
Cnn1, primers CTTCCTCGCCAGGTGTACG (forward) and
TGTGCGGGTGGTGATTGTG (reverse)
N/A N/A
Smtn, primers CGCACGATTGGCAGGGAGA (forward) and
GTCTACTGCACAGTCTCCCAG (reverse)
N/A N/A
Software and Algorithms
Primer3 Software N/A N/A
ImageJ Software NIH N/A
GraphPad Software PRISM5 PRISM5 N/A
SPSS 23.0 Software IBM N/A
FACSDiva Software BD Biosciences N/A
FlowJo V10.0.8 Software Tree Star N/A
MyoVIEW II Software DMT N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giuseppe
Lembo (giuseppe.lembo@uniroma1.it).
EXPERIMENTAL MODEL DETAILS
Murine Models
All animal handling and experimental procedures were performed according to European Community guidelines (EC Council
Directive 2010/63) and the Italian legislation on animal experimentation (Decreto Legislativo D.Lgs 26/2014). All efforts were made
to minimize suffering, and the principles of Replacement, Reduction, and Refinement (i.e., the ‘‘three Rs’’) were applied to all exper-
iments. Mice were housed in an air-conditioned room (temperature 21C ± 1C, relative humidity 60% ± 10%), with lights on from
06:00 to 18:00, and had sawdust as bedding, pellet food, and tap water ad libitum.
Mouse strains used included Smad4f/f (Bardeesy et al., 2006),Myh11-creERT2 (Wirth et al., 2008), Il1r/ (Il1rtm1/mx, The Jackson
Laboratory), Ccr2/ (Ccr2tm1/fc, The Jackson Laboratory). All the mice were backcrossed in the C57BL/6 strain (Charles River
Laboratories). As the Myh11-creERT2 transgene is Y linked and females do not express the Cre recombinase, only male mice
were used. Cre-Lox recombination was induced in 8- to 12-week-old male mice by tamoxifen (T5648, Sigma Aldrich) administration
at the dose of 166mg/kg/day in corn oil by oral gavage for 5 consecutive days. Control groups received corn oil on a similar schedule.
METHODS DETAILS
Administration of Neutralizing Anti-IL-1b Monoclonal Antibody
The IL-1b neutralizing antibody was a donation fromNovartis (Basel, Switzerland). The antibody selectively binds IL-1b, thus blocking
the interaction of the cytokine with its receptors. We treated mice once weekly with a monoclonal mouse anti-mouse IL-1b IgG2a/k
antibody (or a mouse monoclonal IgG2a isotype control), after the last day of tamoxifen or vehicle, with subcutaneous injections of
10 mg/kg body/weight (Denes et al., 2012; Sager et al., 2015).
Blood Pressure Measurement
Blood pressure measurement was performed by tail-cuff plethysmography (BP-2000 Series II, Visitech Systems), as previously
described (Carnevale et al., 2014; Zacchigna et al., 2006), with operators blinded to the experimental group.
Ultrasound Imaging
Ultrasonographic analyses were performed with Vevo2100 (Visualsonics, Fujifilm) equipped by 40 MHz transducer. Mice were anes-
thetized with isoflurane (5% induction and 1.5%–2.0%maintenance). Cardiac function was obtained by standard echocardiography
(Carnevale et al., 2011). For vascular analysis, the ultrasound transducer was placed on the right side of upper anterior mediastinum
for the ascending aorta (Figure S7A), and on the mouse abdomen for the abdominal aorta (Figure S7B). In order to standardize this
projection 3 reference points were used: aortic valve, pulmonary artery, and the brachiocephalic trunk (Figure S7A). B-mode images
were acquired using Visual Sonics presets and measurements of aortic diameters were obtained using Anatomical M-mode. For the
measurement of maximum vessel diameter, sample volume (SV) was positioned on the ascending aorta in correspondence of the
center of the pulmonary artery and perpendicular to vessel wall. In ourmodel, abdominal aneurysms developed only in the suprarenal
region of the vessels (Figure S7B). Thus we acquired B-mode images in correspondence to that point and we measured the
maximum vessel diameter through Anatomical M-mode, placing the SV perpendicular to vessel wall. In vivo mechanical properties
were assessed through calculations of the following standard parameters (Laurent et al., 2006 and Uc¸ar et al., 2015, respectively):
distensibility coefficient ðDCÞ= DA
A  Dpb index=
ln

SBP
DBP

DD
Dd
whereDA = change in lumen area during systole, A = lumen area during diastole,Dp = pulse pressure, SBP = systolic blood pressure,
DBP = diastolic blood pressure, DD = change in lumen diameter during systole, and D = lumen diameter during diastole.
Surgical Procedure and Mounting of Vessels on the Pressure Myograph
For mechanical studies, vessels were excised from mice after cervical dislocation, cleaned of connective and fat tissues, then can-
nulated and mounted on a pressure myograph (DMT, Danish Myotechnology). The experiments were performed in physiological
buffer at 37C of the following composition: 135 mM NaCl, 5 mM KCl, 1.6 mM CaCl2, 1.17 mM MgSO4, 0.44 mM KH2PO4,Immunity 47, 959–973.e1–e9, November 21, 2017 e6
2.6 mM NaHCO3, 0.34 mM Na2HPO4, 5.5 mM D-glucose, 0.025 mM EDTA, 10 mM HEPES (pH 7.4). After 30-minute equilibration,
vessels were transilluminated under an inverted microscope connected to a computerized system for continuous recording of
measures.
Recordings of vessel inner diameters (IDs) and outer diameters (ODs) were taken while increasing the intravascular (transmural)
pressure from 0 to 175 mmHg by steps of 25 mmHg (5 min per step). Recordings were also taken while decreasing the pressure
following the same steps and timing from 175 to 0mmHg. Since the thickness of thewall in the large arteries (like the ascending aorta)
precluded the localization of the inner wall edge in many transilluminated vessels at pressures lower than 100–125mmHg, the ID was
obtained as an indirect measure, calculated by estimating that vessel wall cross-sectional area (WCSA) remains constant throughout
the experimental pressure range. Thus ID can be accurately calculated from OD at any given pressure and from a single measure-
ment of WCSA. Wall/lumen ratio, cross sectional area, circumferential strain, circumferential wall stress, and incremental elastic
modulus were calculated according to the following formulas (Trask et al., 2012):
wall=lumen ratio=

WT
Di

 100cross sectional area ðCSAÞ=p  D
2
e  D2i
4circumferential strain ðεÞ=Di  D0
D0circumferential stress ðsÞ= p  Di
2  WTincremental elastic modulus ðEÞ=Ds
Dε
where WT = wall thickness, De = external diameter, Di = internal diameter, p = pressure in dynes/cm
2, and D0 = original diameter
measured at 0 mmHg.
For IL-1b immunolocalization by confocal microscopy, vessels were prepared with the same procedure described above and kept
pressurized at 125 mmHg for 6 hr in physiological buffer at 37C. As required by the protocol, vessels were incubated with the
following substances: 10 ng/mL LPS from Salmonella Enterica (L5886, Sigma Aldrich), 10 ng/mL recombinant mouse TGF-b
(7666-MB, R&D Systems), 10 mM SB525334 (060916, Sigma Aldrich).
Murine Primary SMC Cultures
Arteries were dissected out from wild-type mice and cleaned from surrounding tissues. Arteries were then incubated in 138 U/mL of
Collagenase type I (CLS-1, Worthington) in DMEM for 40 min at 37C. After removing adventitia, the samples were incubated in
0.25% Trypsin-EDTA (Life Technologies) for 6 min at 37C. The tissue was minced and plated on dishes precoated with 0.1% gelatin
in PBS and cultured in DMEM, 20% FBS and penicillin/streptomycin. For the proposed experiments only cells from passage 1 and
passage 2 were used.
For mRNA analysis, wild-type SMCs were starved in DMEM, 0.1% FBS, penicillin/streptomycin for 16 hr and then treated with LPS
for 6 hr or with 10 ng/mL IL-1b (12340013, Immunotools) for 24 hr, as indicated in figures.
Flow Cytometry
After mice were exsanguinated, aortas were collected and directly analyzed for myeloid staining. For IL-1b analysis, vessels were
incubated for 6 hr in the presence of: 10 ng/mL LPS, 10 ng/mL recombinant mouse TGF-b (7666-MB, R&D Systems), 10 mM
SB525334 (060916, Sigma Aldrich), as specifically indicated in figures.
Single cell suspensions were obtained as previously described (Carnevale et al., 2014; Carnevale et al., 2016). In brief, aortas were
digested with the following cocktail: Collagensae type XI (C7657, Sigma Aldrich), Collagenase type I (C0130, Sigma Aldrich),
Hyaluronidase (H3506, Sigma Aldrich), at 700 rpm for 40 min at 37C. The digested aortas were them passed through a 70 mm sterile
filter (Falcon BD Bioscience) and centrifuged at 1500 rpm for 5 min at 4C. The pellet was resuspended in a buffer containing 0.5%
BSA, 0.1% sodium azide and 2 mM EDTA and number of live cells was assessed using trypan blue and an automated counter
(Countess, Life Technologies). Anti-CD16/CD32 (2.4G2, BD Bioscience) was added for 10 min at room temperature (RT) for blocking
of nonspecific binding and then primary antibodies were incubated for 20 min at RT. After washing, cells were incubated for 10 min
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For myeloid cell staining, the following primary antibodies were used: lineage markers (PE-CD49b (clone DX5), PE-CD45R/B220
(clone RA3-6B2), PE-CD90.2 (clone 53-2.1), PE-CD19 (clone 1D3), PE-NK1.1 (clone PK136), PE-Ter119 (clone TER 119) PE-Ly6G
(clone 1A8) from BD Bioscience), BUV737-CD11b (clone M1/70), BV421-Ly6C (clone AL-21), BUV395-CD45 (clone 30-F11) from
BD Bioscience, BV510-F4/80 (clone BM8) from BioLegend. Monocytes were identified as (Lineage)low(CD45 and CD11b)high
(F4/80)low(Ly6C)high and macrophages as (Lineage)low(CD45 and CD11b)high(Ly6C)low/int(F4/80)high, as exemplified in the gating strat-
egy showed in Figure S7C.
For IL-1b staining, the following primary antibodies for surfacemarkers were used: BUV395-CD45 (clone 30-F11), BUV737-CD11b
(clone M1/70), BV711-CD31 (clone MEC 13.3), BV605-CD29 (clone HM b1-1) from BD Bioscience, BV510-F4/80 (clone BM8) from
BioLegend. For intracellular markers, antibodies were added after fixing and permeabilization of samples with the fixation/permea-
bilization kit BDCytofix/Cytoperm (BDBioscience). The primary antibodies for intracellular staining were as follow: FITC-aSMA (clone
1A4, Abcam) and PE-IL-1b/IL-1F2 (clone 166931, R&DSystems) or its isotype PE-IgG2B (clone 141945, R&DSystems). Cells positive
for IL-1b were analyzed using the fluorescence minus one (FMO) gating on SMCs (CD45CD31aSMA+), fibroblasts
(CD45CD31CD29+), endothelial cells (CD45CD31+), monocytes and macrophages (CD45+ CD11b+), as exemplified in the gating
strategy shown in Figure S7D. Data from the entire sample were acquired on FACSCelesta flow cytometer with FACSDiva software
(BD Biosciences) and analyzed using FlowJo software (V10.0.8, Tree Star).
Histological Analysis
Hematoxylin & eosin (H&E) and Weigert’s staining were carried out on paraformaldehyde-fixed (4% overnight at 4C) paraffin-
embedded or frozen sections (7–10 mm) using standard procedures. For Alcian Blue staining frozen aorta sections were fixed in
10% paraformaldehyde and stained with 1% solution for 3 hr at RT. For immunoperoxidase staining, the anti-rabbit VectaStain
Kit (Vector laboratories) was used following manufacturer’s protocol.
For immunofluorescence frozen sections were treated with MetOH/Aceton (1:1) at 20C for 10’ before incubation with blocking
solution. Slides were incubated at 4C overnight with primary antibody and for 2 hr at RT with secondary antibody, mounted, and
examined in a Leica SP5 confocal microscope or a Zeiss 780 confocal microscope.
Primary antibodies used for immunofluorescence or immunohistochemistry were: rabbit anti-Smad4 (1:200; Santa Cruz); rat anti-
ER-TR7 (1:250; Santa Cruz); mouse anti-a-SMA (1:200; Sigma Aldrich); rat anti-CD45 (1:250; Abd Serotec); rat anti-CD68 (1:250; Abd
Serotec); rat anti-CD3 (1:250; eBioscience); rat anti-CD11b (1:250; Abd Serotec); rabbit anti-Collagen I (1:1,600; Acris); rabbit anti-IL-
1b (1:1,000; GeneTex); rabbit anti-IL-1R (1:100; Abcam). Secondary antibodies used were Alexa488 anti-mouse (1:200), Cy3 anti-rat
(1:300), Cy3 anti-rabbit (1:200) (all Jackson Immunoresearch). Nuclei were stained with Hoechst (33258, Sigma Aldrich) or DAPI
Vectashield (Vector laboratories) as indicated in figure legends.
IL-1b staining was quantified by automated fluorescence signal detection analysis and expressed as% of signal intensity in SMCs
area of the vessels (Figures S7E and S7F). Quantitative analysis of IL-1b staining was performed by measurement of stained area
(Figure S7E) over global SMCs area of the vessel, labeled with anti-a-SMA (Figure S7F, dashed area) with ImageJ software (NIH).
Data are expressed as mean percentage ± SEM.
Protein Analysis
Proteins were extracted from aortas using the ‘‘Total protein extraction kit’’ (Merck Millipore) as indicated by the manufacturer, sup-
plemented with protease and phosphatase inhibitors (Roche). Protein samples were quantified with Pierce BCA Protein Assay Kit
(23227, ThermoScientific), loaded and separated in pre-cast NuPAGE 10% Bis-Tris Gel (Novex, ThermoScientific) and blotted
into PVDF membranes (ThermoScientific). The filters were blocked and incubated with primary and secondary antibodies. Reactive
bands were revealed by LiteAblot EXTEND or LiteAblot PLUS (Euroclone), and quantified using the ImageJ software.
Primary antibodies used were: mouse anti-Smad4 (1:200; Santa Cruz); mouse anti-b-actin (1:4000; Sigma Aldrich); rabbit anti-
P-Smad2 (1:1,000; Cell Signaling); rabbit anti-P-Smad1/5/8 (1:1,000; Millipore); rabbit anti-P-JNK (1:500; Cell Signaling); rabbit
anti-P-p38 (1:1,000 Cell Signaling); rabbit anti-P-ERK1/2 (1:500; Santa Cruz); rabbit anti-P-TAK1 (1:500, Cell Signaling); rabbit
anti-TAK1 (1:1000, Bethyl); rabbit anti-RelA/p65 (1:1000; Santa Cruz); rabbit anti-P-(S536)RelA/p65 (1:1,000; Cell Signaling).
Secondary antibodies (Bethyl) were used 1:1,000.
Gene Expression Analysis
RNA was extracted from the media of the ascending aorta by Trizol (Invitrogen), after removal of adventitia layer. Real-time RT-PCR
reactions were run with the Rotor-Gene Q Real time PCR system (QIAGEN). Relative expression amounts were calculated using the
DDCt method with normalization to the concentration of S16 in the same samples. Data are presented as fold changes compared to
the control groups. Sequences of specific primers were designed by Primer3 software and are listed in the Key Resources Table.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample size for all the experiments was pre-estimated from previously published research and from pilot experiments performed in
our laboratories. Data are presented as mean ± SEM. Data distribution was assessed with the Shapiro-Wilk normality test and
D’Agostino Pearson test, and assumption of homogeneity of variance was tested using Levene’s test for equality of variances.
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significance was assessed with the appropriate test according to each experimental design, as detailed in figure legends. After as-
sessing distribution of each data setting, we applied Student’s t test for independent samples orMann-Whitney for independent sam-
ples, according to the experimental design and as specified in the figure legends. Multiple group analysis was performed with one-
way ANOVA or two-way ANOVA followed by Bonferroni’s post hoc for data with normal distribution. Analysis for repeated-measures
was applied when required by the experimental setting. Multiple group analysis of non-parametric data was performed with Kruskal-
Wallis test followed by Dunn’s multiple comparison test. p < 0.05 was considered significant. Statistical analyses were performed
with SPSS 23.0 (IBM Software) and graphs were made with GraphPad Software PRISM5.e9 Immunity 47, 959–973.e1–e9, November 21, 2017
